Tumour markers of prognosis in colorectal cancer

British Journal of Cancer

Volumn 79, Issue 2, 1999, Pages 191-203

  McLeod, H L ^a   Murray, G I ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Colorectal cancer; Immunohistochemistry; Prognosis; Tumour markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; HERMES ANTIGEN; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; RALTITREXED; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; UROKINASE; UVOMORULIN; VASCULOTROPIN;

APOPTOSIS; BLOOD GROUP LEWIS SYSTEM; CELL PROLIFERATION; CHROMOSOME 18Q; COLORECTAL CANCER; HETEROZYGOSITY LOSS; HUMAN; ONCOGENE; ONCOGENE C ERB; ONCOGENE C MYC; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0032920520     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690033     Document Type: Review

References (104)

1. Amaya H, Tanigawa N, Lu C, Matsumura M, Shimomatsuya T, Horiuchi T and Muroaka R (1997) Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 119: 227-235
2. Ambiru S, Miyazaki M, Ito H, Nakagawa K, Shimizu H, Nukui Y, Nozawa S, Okuno A, Yoshitomi H and Nakajima N (1997) A prospective study of prognostic value of type IV collagenase in colorectal cancer tissue. Dig Dis Sci 42: 1660-1665
3. Anderson SN, Lovig T, Breivik J, Lund E, Guadernack G, Meling GI and Rognum TO (1996) K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol 32: 62-69
4. Apolinario RM, van der Valk P, de Jong JS, Deveille W, Van Arkotte J, Dingemans A-MC, Van Mourik JC, Postmus PE, Pinedo HM and Giaccone G (1997) Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15: 2456-2466
5. Arribas R, Capellà G, Tórtola S, Masramon L, Grizzle WE, Perucho M and Peinado MA (1997). Assessment of genomic damage in colorectal cancer by DNA fingerprinting: prognostic applications. J Clin Oncol 15: 3230-3240
6. Astler VB and Coller FA (1954) The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 192: 846-850
7. Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, Multani AS, Pathak S, Benson A, Haller D and Heerdt BG (1997) Low-level c-myc amplifications in human colonic carcinoma cell lines and tumours: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57: 1769-1775
8. Baas IO, Mulder JR, Offerhaus GJA, Vogelstein B and Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172: 5-12
9. Baretton GB, Vogt M, Muller C, Diebold J, Schneiderbanger K, Schmidt M and Lohrs U (1996a) Prognostic significance of p53 expression, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (stages IB and II). Scand J Gastroenterol 31: 481-489
10. Baretton GB, Diebold J, Christoforis G, Vogt M, Müller C, Dopfer K, Schneiderbanger K, Schmidt M and Löhrs U (1996b) Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 77: 255-264
11. Bartik Z, Nordenskiöld BO and Sun Z-F (1997) p53 overexpression as a prognostic factor in patients with Dukes' B colorectal adenocarcinoma. Int J Oncol 11: 1019-1023
12. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, Taylor GR, Dixon MF and Quirke P (1993) Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 104: 57-64
13. Belluco C, Guillem JG, Kemeny N, Huang Y, Klimstra D, Berger MF and Cohen AM (1996) p53 Nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14: 2696-2701
14. Benhattar J, Losi L, Chaubert P, Givel J-C and Costa J (1993) Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 104: 1044-1048
15. Bennett MA, Kay EW, Mulcahy H, O'Flaherty L, O'Donoghue, DP, Leader M and Croke DT (1995) ras and p53 in the prediction of survival in Dukes' stage B colorectal carcinoma. J Clin Pathol 48: M310-M315
16. Bhatavdekar JM, Patel DD, Ghosh N, Chikhlikar PR, Trivedi TI, Suthar TP, Doctor SS, Shah NG and Balar DB (1997) Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 40: 785-790
17. Bosari S and Viale G (1995) The clinical significance of p53 aberrations in human tumors. Virchows Arch A Pathol Anat Histopathol 427: 229-241
18. Bosari S, Viale G, Bossi P, Maggioni M, Coggi G, Murray JJ and Lee AKC (1994) Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86: 681-687
19. Bosari S, Moneghini L, Graziani D, Lee AKC, Murray JJ, Coggi G and Viale G (1995) Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Human Pathol 26: 534-540
20. Brett MC, Pickard M, Green B, Howel-Evans A, Smith D, Kinsella A and Poston G (1996) p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Sur Oncol 22: 182-185
21. Chambers AF and Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270
22. Cohen AM, Tremiterra S, Candela F, Thaler HT and Sigurdson ER (1991) Prognosis of node-positive colon cancer. Cancer 67: 1859-1861
23. Costa A, Doci R, Machen C, Bignami P, Faranda A, Gennari L and Silvestrini R (1997) Cell proliferation-related markers in colorectal liver metastases: correlation with patients prognosis. J Clin Oncol 15: 2008-2014
24. Cox LS and Lane DP (1995) Tumor suppressors, kinases and clamps - how p53 regulates the cell-cycle in response to DNA-damage. Bioessays 17: 510-508
25. Dix BR, Robbins P, Soong R, Jenner D, House AK, Lacopetta BJ, and The General Surgeons at Sir Charles Gairdner Hospital (1994) The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 59: 747-751
26. Dorudi S, Hanby AM, Poulsom R, Northover J and Hart IR (1995) Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 71: 614-616
27. Elnatan J, Goh H-S and Smith DR (1996) C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer 32A: 491-197
28. Fearon ER and Vogelstein BA (1990) The genetic model for colorectal tumorigenesis. Cell 61: 759-767
29. Findlay MPN, Cunningham D, Morgan G, Clinton S, Hardcastle A and Aherne GW (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75: 903-909
30. Ganesh S, Sier CFM, Heerding MM, Vankrieken JHJM, Griffioen G, Welvaart K, van de Velde CJ, Verheijen JH, Lamers, CB and Verspaget HW (1996) Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer 75: 1793-1801
31. Goh H-S, Yao J and Smith DR (1995) p53 Point mutation and survival in colorectal cancer patients. Cancer Res 55: 5217-5221
32. Griffiths L and Stratford IJ (1997) Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer 76: 689-693
33. Hall PA and Lane DP (1994) p53 in tumour pathology: can we trust immunohistochemistry? - Revisited! J Pathol 172: 1-4
34. Hermanek P, Wiebelt H, Staimner D and Riedl S (1995) Prognostic factors of rectum carcinoma - experience of the German multicentre study SGCRC. German Study Group Colo-Rectal Carcinoma. Tumori 81: 60-64
35. Hoffmann D, Moore J and Roder D (1997) Trends in survival from colonic cancer: The impact of subspecialization. Aus N Z J Surgery 67: 842-845
36. Ishimuru G, Ookawa K, Yamaguchi N, Sakamoto M, Hirohashi S, Muto T and Yokota J (1994) Allelic losses associated with the metastatic potential of colorectal carcinoma. Int J Oncol 5: 267-273
37. Jackman AL, Kelland LR, Kimbell R, Brown M, Gibson W, Aherne GW, Hardcastle A and Boyle FT (1995) Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (tomudex) in one mouse and three human cell lines. Br J Cancer 71: 914-924
38. Jen J, Kim HG, Piantadosi S, Liu ZF, Lecitt RC, Sistonen P, Kinzler KW, Vogelstein B and Hamilton SR (1994) Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331: 213-221
39. Johnston PG, Drake JC, Trepel J and Allegra CJ (1992) Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52: 4306-4312
40. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647
41. Johnston PG, Lenz H-J, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumours. Cancer Res 55: 1407-1412
42. Kang SM, Maeda K, Chung YS, Onodda N, Ogawa Y, Takatsuka S, Ogawa M, Sawada T, Nakata B, Nishiguchi Y, Ikehara T, Okuno M and Sowa M (1997) Vascular endothelial growth factor expression correlates with hematogenous metastasis and prognosis in colorectal carcinoma. Oncol Rep 4: 381-384
43. HFR 2/neu correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112: 1103-1113
44. Kay EW, Mulcahy H, Walsh CB, Leader M and O'Donoghue D (1994) Cytoplasmic c-erb B2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology 25: 455-461
45. Khine K, Goh H-S and Smith DR (1995) Prognostic significance of chromosome 5q and 17p allelic deletion in colorectal adenocarcinomas. Int J Oncol 7: 631-635
46. Kitadai Y, Ellis LM, Tucker SL, Greene GF, Bucana CD, Cleary KR, Takahashi Y, Tahara E and Fidler IJ (1996) Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Path 149: 1541-1551
47. Kochhar R, Halling KC, McDonnell S, Schaid DJ, French AJ, O'Connell MJ, Nagorney DM and Thibodeau SN (1997) Allelic imbalance and microsatellite instability in resected Dukes' D colorectal cancer. Diagn Mol Pathol 6: 78-84
48. Kornmann M, Link KH, Lenz H-J, Pillasch J, Metzger R, Butzer U, Leder GH, Weindel M, Safi F, Danenberg KD, Beger HG and Danenberg PV (1997) Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 118: 29-35
49. Koshida Y, Saegusa M and Okayasu I (1997) Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer 75: 367-373
50. Kressner ULF, Lindmark G, Gerdin B, Pahlman L and Glimelius B (1996) Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 16: 951-958
51. Kumar V, Bustin SA and Mckay IA (1995) Transforming growth factor-alpha. Cell Biol Int 19: 373-388
52. Lanza G, Maestri I, Dubini A, Gafa R, Santini A, Ferretti S and Cavazzini L (1996) P53 expression in colorectal cancer. Relation to tumor type, DNA ploidy pattern, and short-term survival. Am J Clin Pathol 105: 604-612
53. Lawrence DA (1996) Transforming growth factor-beta a general review. Eur Cytokine Network 7: 363-374
54. Leahy DT, Salman R, Mulcahy H, Sheahan K, O'Donoghue DP and Parfrey NA (1996) Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 180: 364-370
55. Leichman CG, Lenz H-J, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229
56. Linden MD, Nathanson DS and Jacobson G (1996) Lack of prognostic significance of epidermal growth factor receptor expression in Dukes' B colorectal carcinomas. Lab Invest 74: 61A:343
57. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM and Pagano M (1997) Increased proteasome-dependent degradation of the cyclin dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 3: 231-234
58. Lowe SW, Ruley HE, Jacks T and Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967
59. Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H, Brown D, Srivastava S and Grizzle WE (1997) Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 74: 346-358
60. Markowitz S, Hines JD, Lutterbaugh J, Mycroff L, Mackay W, Gordon N, Rustum Y, Luna E and Kleinerman J (1995) Mutant K-ras oncogenes in colon cancers do not predict patient's chemotherapy response or survival. Clin Cancer Res 1: 441-445
61. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K and Ludwig H (1993) The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71: 2454-2460
62. McArdle CS and Hole D (1991) Impact of variability among surgeons on post-operative morbidity and mortality and ultimate survival. Br Med J 302: 1501-1505
63. Miller F, Heimann TM, Quish A, Pyo DJ, Szporn A, Martinelli G and Fasy TM (1992) Ras and c-myc protein expression in colorectal carcinoma. Dis Colon Rectum 35: 430-435
64. Miyahara M, Saito T, Kaketani K, Sato K, Kuwahara A, Shimoda K and Kobayashi M (1991) Clinical significance of ras p21 overexpression for patients with an advanced colorectal cancer. Dis Colon Rectum 34: 1097-1102
65. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA and Graff J (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321-326
66. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP and Sheahan K (1994) Urokinase type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344: 583-584
67. Mulder JWR, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJ and Pals ST (1994) Colorectal cancer prognosis and expression of exon-v6 containing CD44 proteins. Lancet 344: 1470-1472
68. Murray GI, Duncan ME, O'Neil P, Melvin WT and Fothergill JE (1996) Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med 2: 461-162
69. Nagai MA, Habr-Gama A, Oshima BS and Bretani MM (1992) Association of genetic alterations of c-myc, c-fos, and c-Ha-ras proto-oncogenes in colorectal tumors. Frequency and clinical significance. Dis Colon Rectum 35: 444-451
70. Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, Kabuto T, Iwanaga T, Matsushita Y and Irimura T (1993) Increased expression of Sialyl Lewis antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 53: 3632-3637
71. Neoptolemos JP, Oates GD, Newbold KM, Robson AM, McConkey C and Powell J (1995) Cyclin/proliferation cell nuclear antigen immunohistochemistry does not improve the prognostic power of Dukes' or Jass' classifications for colorectal cancer. Br J Surg 82: 184-187
72. Ofner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Tötsch M, Böcker W, Jasani B and Schmid KW (1995) Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 72: 981-985
73. Ogunbiyi OA, Goodfellow PJ, Gagliardi G, Swanson PE, Birnbaum EH, Fleshman JW, Kodner IJ and Moley JF (1997) Prognostic value of chromosome 1 p allelic loss in colon cancer. Gastroenterology 113: 761-766
74. Ogunbiyi OA, Goodfellow PJ, Herfarth K, Gagliardi G, Swanson PE, Birnbaum EH, Read TE, Fleshman JW, Kodner IJ and Moley JF (1998) Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16: 427-433
75. Paradiso A, Rabínovich M, Vallejo C, Machiavelli M, Romero A, Perez J, Lacava J, Cuevas MA, Rodriquez R, Leone B, Sapia MG, Simone G and De Lena M (1996) p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer 69: 437-441
76. Parkin DM, Pisani P and Ferlay J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54: 594-606
77. Poller DN, Baxter KJ and Shepherd NA (1997) p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 75: 87-93
78. Pricolo VE, Finkelstein SD, WU T-T, Keller G, Bakker A, Swalsky PA and Bland KI (1996) Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg 171: 41-46
79. Reinbach DH, McGregor JR, Murray GD and Odwyer PJ (1994) Effect of the surgeons speciality interest on the type of resection performed for colorectal-cancer. Dis Colon Rectum 37: 1020-1023
80. Robson H, Anderson E, James RD and Schofield PF (1996) Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 74: 753-758
81. Schneider HJ, Sampson SA, Cunningham D, Norman AR, Andreyev HJN, Tilsed JVT and Clarke PA (1997) Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Br J Cancer 75: 427-431
82. Schumacher U, Higgs D, Loizidou M, Pickering R, Leathem A and Taylor I (1994) Helix pomatia agglutinin binding is a useful prognostic indicator in colorectal carcinoma. Cancer 74: 3104-3107
83. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G Jr, Jessup JM, Loda M and Summerhayes IC (1996) The DCC protein and prognosis in colorectal cancer. N Engl J Med 335: 1727-1732
84. Sinicrope FA, Hart J, Michelassi F and Lee JJ (1995) Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1: 1103-1110
85. Smith DR and Goh H-S (1996) Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene. Clin Cancer Res 2: 1049-1053
86. Smith DR, Elnatan J, Yao J and Goh H-S (1996) Point mutation of the c-Ki-ras proto-oncogene and the p53 tumour suppressor gene in distal colonic adenocarcinomas. Int J Oncol 8: 1165-1169
87. Soong R, Grieu F, Robbins P, Dix B, Chen D, Parsons R, House A and Lacopetta B (1997) P53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3: 1405-1411
88. Span M, Moerkerk PT, De Goeij AF and Arends JW (1996) A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 69: 241-245
89. Spitz FR, Giacco GG, Hess K, Larry L, Rich TA, Janjan N, Cleary KR and Skibber JM (1997) P53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res 3: 1658-1690
90. Sun XF, Wingren S, Carstensen JM, Stäl O, Hatschek T, Boeryd B, Nordenskjöld B and Zhang H (1991) Ras p21 expression in relation to DNA ploidy, s-phase fraction and prognosis in colorectal adenocarcinoma. Eur J Cancer 27: 1646-1649
91. Sun XF, Carsten JM, Zhang H, Stal O, Wingern S, Hatschek T and Nordenskjold B (1992) Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340: 1369-1373
92. Sun XF, Carstensen JM, Stal O, Zhang H and Nordenskjold B (1995) c-erb B2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcenoma. APMIS 103: 309-315
93. Sun XF, Carstensen JM, Stal O, Zhang H and Nordenskjold B (1996) Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2, p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. Int J Cancer 69: 5-8
94. Takahashi Y, Tucher SL, Kitadai Y, Koura AN, Bucana CD, Cleary KR and Ellis LM (1997) Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132: 541-546
95. Takebayashi Y, Akiyama S-I, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F and Aikou T (1996) Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110-1117
96. Wadler S, Bajaj R, Neuberg D, Agarwal V, Haynes H and Benson ALB (1997) Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: A study of the Eastern Cooperative Oncology Group (EST 2292). Cancer J Scientific Am 3: 284-289
97. Witzig TE, Lopfinzi CL, Gonchoroff NJ, Reiman HM, Cha SS, Wieand HS, Katzmann JA, Paulsen JK and Moertel CG (1991) DNA ploidy and cell kinetic measurements as predictors of reoccurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68: 879-888
98. Wolmark N, Wieand HS, Rockette HE, Fisher B, Glass A, Lawrence W, Lerner H, Cruz AB, Volk H, Shibata H, Evans J and Prager D (1983) The prognostic significance of tumour location and bowel obstruction in Dukes' B and C colorectal cancer. Ann Surg 198: 743-750
99. Wynford-Thomas D (1992) p53 in tumour pathology: can we trust immunohistochemistry? J Pathol 166: 329-330
100. Yamaguchi A, Nakagawara G, Kurosaka Y, Nishimura G, Yonemura Y and Miyazaki I (1993) P53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 68: 399-402
101. Yamaguchi A, Urano T, Goi T, Saito M, Takeuchi K, Hirose K, Nakagawara G, Shiku H and Furukawa K (1996) Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 14: 1122-1127
102. Younes M, Fernandez L and Lechago J (1996) Transforming growth factor alpha (TGF-α) expression in biopsies of colorectal carcinoma is a significant prognostic indicator. Anticancer Res 16: 1999-2004
103. Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillem JG, Cordon-Cardo C and Cohen AM (1994) P53 nuclear overexpression - an independent predictor of survival in lymph node positive colorectal cancer patients. J Clin Oncol 12: 2043-2050
104. Zeng ZS, Huang Y, Cohen AM and Guillem JG (1996) Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 14: 3133-3140